$HSTC
HST Global Inc

2021 Form 10-K Financial Statement

#000167479622000007 Filed on March 04, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $145.7K $94.66K $208.0K
YoY Change -29.94% 271.51% 37.24%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $145.7K $94.66K $208.0K
YoY Change -29.94% 271.51% 37.23%
Operating Profit -$145.7K -$208.0K
YoY Change -29.94% 37.23%
Interest Expense $2.642K -$540.00 $1.014K
YoY Change 160.55% -105.67%
% of Operating Profit
Other Income/Expense, Net -$2.642K -$1.014K
YoY Change 160.55% -100.18%
Pretax Income -$148.4K -$95.20K -$209.0K
YoY Change -29.01% 273.63% -148.99%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$148.4K -$95.20K -$209.0K
YoY Change -29.01% 273.63% -148.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share -$28.27K -$18.14K -$43.80K
COMMON SHARES
Basic Shares Outstanding 5.249M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $230.00 $660.00 $660.00
YoY Change -65.15% -66.33% -66.33%
Cash & Equivalents $230.00 $660.00 $660.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $230.00 $660.00 $660.00
YoY Change -65.15% -66.24% -66.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $230.00 $660.00 $660.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $230.00 $660.00 $660.00
YoY Change -65.15% -66.24% -66.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $242.3K $126.4K $126.4K
YoY Change 91.69% 2244.9% 2244.9%
Accrued Expenses $3.660K $1.010K $1.010K
YoY Change 262.38%
Deferred Revenue
YoY Change
Short-Term Debt $55.08K $25.68K $25.68K
YoY Change 114.49%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $301.0K $153.1K $153.1K
YoY Change 96.64% 2742.77% 2740.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $301.0K $153.1K $153.1K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $301.0K $153.1K $153.1K
YoY Change 96.64% 2742.77% 2740.07%
SHAREHOLDERS EQUITY
Retained Earnings -$5.575M
YoY Change 3.89%
Common Stock $5.248K
YoY Change 23.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$300.8K -$152.4K -$152.4K
YoY Change
Total Liabilities & Shareholders Equity $230.00 $660.00 $660.00
YoY Change -65.15% -66.24% -66.33%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$148.4K -$95.20K -$209.0K
YoY Change -29.01% 273.63% -148.99%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$29.84K -$90.00 -$26.97K
YoY Change 10.62% -99.4% -70.65%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $29.40K 0.000 $25.68K
YoY Change 14.51% -72.64%
NET CHANGE
Cash From Operating Activities -$29.84K -90.00 -$26.97K
Cash From Investing Activities $0.00 0.000 $0.00
Cash From Financing Activities $29.40K 0.000 $25.68K
Net Change In Cash -$435.00 -90.00 -$1.295K
YoY Change -66.41% -99.4% -166.41%
FREE CASH FLOW
Cash From Operating Activities -$29.84K -$90.00 -$26.97K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Entity File Number
EntityFileNumber
000-15303
CY2021 dei Entity Registrant Name
EntityRegistrantName
HST GLOBAL, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
73-1215433
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
150 Research Drive
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Hampton
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23666
CY2021 dei City Area Code
CityAreaCode
757
CY2021 dei Local Phone Number
LocalPhoneNumber
766-6100
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q2 dei Entity Public Float
EntityPublicFloat
96779 usd
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5248582 shares
CY2021 dei Auditor Firm
AuditorFirmId
76
CY2021 dei Auditor Name
AuditorName
Turner, Stone & Company, LLP
CY2021 dei Auditor Location
AuditorLocation
Dallas, Texas
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
225 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
660 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
225 usd
CY2020Q4 us-gaap Assets Current
AssetsCurrent
660 usd
CY2021Q4 us-gaap Assets
Assets
225 usd
CY2020Q4 us-gaap Assets
Assets
660 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
0 usd
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4918 usd
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
242275 usd
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
121475 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
55077 usd
CY2020Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
25676 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3656 usd
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1014 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
301008 usd
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
153083 usd
CY2021Q4 us-gaap Liabilities
Liabilities
301008 usd
CY2020Q4 us-gaap Liabilities
Liabilities
153083 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5248582 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5248582 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5248582 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5248582 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5248 usd
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5248 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5417236 usd
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5417236 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5723267 usd
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5574907 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-300783 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-152423 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
225 usd
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
660 usd
CY2021 us-gaap Revenues
Revenues
0 usd
CY2020 us-gaap Revenues
Revenues
0 usd
CY2021 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
120000 usd
CY2020 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
180000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25718 usd
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27978 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
145718 usd
CY2020 us-gaap Operating Expenses
OperatingExpenses
207978 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-145718 usd
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-207978 usd
CY2021 us-gaap Interest Expense
InterestExpense
2642 usd
CY2020 us-gaap Interest Expense
InterestExpense
1014 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2642 usd
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1014 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-148360 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-208992 usd
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5248582 shares
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4771066 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-152423 usd
CY2021 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
-148360 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-300783 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-148360 usd
CY2020 us-gaap Profit Loss
ProfitLoss
-208992 usd
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0 usd
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4918 usd
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1007 usd
CY2021 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
120800 usd
CY2020 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
120000 usd
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2642 usd
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1014 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29836 usd
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26971 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
29401 usd
CY2020 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
25676 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29401 usd
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25676 usd
CY2021 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-435 usd
CY2020 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1295 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
660 usd
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1955 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
225 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
660 usd
CY2021 us-gaap Interest Paid
InterestPaid
0 usd
CY2020 us-gaap Interest Paid
InterestPaid
0 usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021 fil Conversionof Accounts Payable
ConversionofAccountsPayable
0 usd
CY2020 fil Conversionof Accounts Payable
ConversionofAccountsPayable
0 usd
CY2021 fil Conversionof Notes Payable
ConversionofNotesPayable
0 usd
CY2020 fil Conversionof Notes Payable
ConversionofNotesPayable
0 usd
CY2021 fil Derecognition Of Related Party Debt
DerecognitionOfRelatedPartyDebt
0 usd
CY2020 fil Derecognition Of Related Party Debt
DerecognitionOfRelatedPartyDebt
0 usd
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt"><b>NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES</b></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. (“the Company”) was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc. At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">HST Global, Inc. is an integrated Health and Wellness Biotechnology company with a plan to develop and/or acquire a network of Wellness Centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases.  In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases.</p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;text-align:justify">To date we have been unable to initiate our original business plan.  While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams. </p>
CY2021 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify"><span style="border-bottom:1px solid #000000">Basis of Presentation</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The accompanying consolidated financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K.</p>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify"><span style="border-bottom:1px solid #000000">Use of Estimates</span></p> <p style="font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt;color:#000000;text-align:justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
242275 usd
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
121475 usd
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-31156 usd
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-43888 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
31156 usd
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
43888 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1223277 usd
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1192121 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
113692 usd
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
113692 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1109585 usd
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1078429 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd

Files In Submission

Name View Source Status
0001674796-22-000007-index-headers.html Edgar Link pending
0001674796-22-000007-index.html Edgar Link pending
0001674796-22-000007.txt Edgar Link pending
0001674796-22-000007-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hstc-20211231.htm Edgar Link pending
hstc-20211231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hstc-20211231_def.xml Edgar Link unprocessable
hstc-20211231_cal.xml Edgar Link unprocessable
hstc-20211231_lab.xml Edgar Link unprocessable
hstc-20211231_pre.xml Edgar Link unprocessable
hstc-20211231_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending